Gerber Hans-Peter reported tax withholding involving 1,345 shares of SUTRO BIOPHARMA, INC. at $15.34 for −$20.6k on Sep 18, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
CHIEF SCIENTIFIC OFFICER
CHIEF SCIENTIFIC OFFICER
Filed Sep 22, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$20,632.30Shares × reported price
Shares traded
1,345Common Stock
Price per share
$15.34Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
12,367Direct
Trade date
Sep 18, 2026Tax withholding
Filed
Sep 22, 2026, 4:09 PM ET4-day reporting delay
Accession
0001992979-26-000004Code F · Transaction 227457
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Option exercise3,750$0.00$0Trade 227456
Sep 18, 2026Option exercise3,750$0.00$0Trade 227458
3 transaction rows in this filing. Joint filers share the same rows.

STRO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
STRO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −0.2%30d −33%90d180d1y

Footnotes in full

F1: The reported total includes 444 shares of Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). F2: Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of restricted stock units; does not represent a sale by the reporting person. F3: Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4: The RSUs vested or vest as to 1/4 of the total award annually, with the first tranche vested on September 18, 2024, subject to the reporting person's continued service through each vesting date.